3-(2-aminobenzamido)indazole | 185993-29-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-aminobenzamido)indazole
• 英文别名: 2-amino-N-(1H-indazol-3-yl)benzamide
• CAS: 185993-29-7
• 化学式: C₁₄H₁₂N₄O
• 分子量: 252.275
• InChiKey: SCRIVIIUSSVXFD-UHFFFAOYSA-N

物化性质

• 沸点：
  436.6±25.0 °C(predicted)
• 密度：
  1.431±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.8
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-aminobenzamido)indazole 在 potassium nitrite 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 以81%的产率得到3-(indazol-3-yl)-1,2,3-benzotriazin-4(3H)-one
  参考文献：
  名称：

  Synthesis, Crystallographic Studies and Biological Evaluation of Some 2-Substituted 3-Indazolyl-4(3H)-quinazolinones and 3-Indazolyl-4(3H)-benzotriazinones

  摘要：

  A number of new 3-(indazol-3 and 5-yl)-4(3H)-quinazolinone and 4(3H)-benzotriazinone derivatives were prepared by reaction of 3- or 5-(2-aminobenzamido)indazole with ethyl orthoesters and nitrous acid respectively. Structures were established on the basis of analytical and spectroscopic data. Single-crystal X-ray analysis confirmed the quinazolinone structure of compounds (5). The 4(3H)-quinazolinones and 4(3H)-benzotriazinones were tested at 200 mu g/ml for antimicrobial activity against C. albicans, C. tropicalis and S. aureus, at 100 mu M for their antitumor effect on human-lymphoblast-like cells and finally at 500 mu M for 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD) inhibition.

  DOI：

  10.3987/com-96-7549
• 作为产物：
  描述：

  3-氨基吲唑 在 palladium on activated charcoal 吡啶 、 氢气 作用下， 以 乙醇 为溶剂， 5.0 ℃ 、310.27 kPa 条件下， 反应 24.0h， 生成 3-(2-aminobenzamido)indazole
  参考文献：
  名称：

  Synthesis, Crystallographic Studies and Biological Evaluation of Some 2-Substituted 3-Indazolyl-4(3H)-quinazolinones and 3-Indazolyl-4(3H)-benzotriazinones

  摘要：

  A number of new 3-(indazol-3 and 5-yl)-4(3H)-quinazolinone and 4(3H)-benzotriazinone derivatives were prepared by reaction of 3- or 5-(2-aminobenzamido)indazole with ethyl orthoesters and nitrous acid respectively. Structures were established on the basis of analytical and spectroscopic data. Single-crystal X-ray analysis confirmed the quinazolinone structure of compounds (5). The 4(3H)-quinazolinones and 4(3H)-benzotriazinones were tested at 200 mu g/ml for antimicrobial activity against C. albicans, C. tropicalis and S. aureus, at 100 mu M for their antitumor effect on human-lymphoblast-like cells and finally at 500 mu M for 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD) inhibition.

  DOI：

  10.3987/com-96-7549

文献信息

• Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof
  申请人：——

  公开号：US20040014802A1

  公开（公告）日：2004-01-22

  The present invention relates to the novel indazole derivatives of general formula (I): 1 in which: R is either O, S or NH; R3 is an alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryl, heterocycle, cycloalkyl, alkenyl, etc. radical; these radicals being optionally substituted with one or more substituents; R4, R5, R6 and R7 are chosen, independently of each other, from the following radicals: hydrogen, halogen, CN, NO 2 , NH 2 , OH, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO 2 R8, NHSO 2 R8, SO 2 NR8R9, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, cycloalkyl, alkenyl, etc.; these radicals being optionally substituted with one or more substituents.

  本发明涉及一般式(I)的新型吲唑衍生物： 1 其中：R为O、S或NH；R3为烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、芳基、杂环、环烷基、烯基等基团；这些基团可以选择性地被一个或多个取代基取代；R4、R5、R6和R7分别选择自以下基团：氢、卤素、CN、NO 2 、NH 2 、OH、COOH、C(O)OR8、—O—C(O)R8、NR8R9、NHC(O)R8、C(O)NR8R9、NHC(S)R8、C(S)NR8R9、SR8、S(O)R8、SO 2 R8、NHSO 2 R8、SO 2 NR8R9、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基、芳基烷基、杂芳基、杂芳基烷基、杂环、环烷基、烯基等；这些基团可以选择性地被一个或多个取代基取代。
• Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
  申请人：Martina Katia

  公开号：US20060106083A1

  公开（公告）日：2006-05-18

  Compounds which are indazole derivatives and pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them, as well as combinatorial libraries of indazole derivatives, as set forth in the specification, are disclosed; these compounds or compositions may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  这些是关于吲唑衍生物及其药用盐的化合物，以及包含它们的药物组合物，以及吲唑衍生物的组合化合物库的说明；这些化合物或组合物可能在治疗由改变的蛋白激酶活性引起和/或与之相关的疾病方面有用，如癌症、细胞增殖紊乱、阿尔茨海默病、病毒感染、自身免疫疾病和神经退行性疾病。
• Synthesis and biological evaluation of new indazole derivatives
  作者：Salvatore Plescia、Demetrio Raffa、Fabiana Plescia、Giovanni Casula、Benedetta Maggio、Giuseppe Daidone、Maria Valeria Raimondi、Maria Grazia Cusimano、Gabriella Bombieri、Fiorella Meneghetti

  DOI：10.3998/ark.5550190.0011.a14

  日期：——

  New N-methyl and N-ethyl substitutions in the indazole nucleus are reported by reacting 3-(2aminobenzamido)indazole and the appropriate trimethyl/triethyl orthobenzoate. Single crystal Xray analysis confirms the N-ethylation position for the 3-(1-ethyl-1H-indazol-3-yl)-2phenylquinazolin-4(3H)-one derivative 3f. Compounds 11a-d and 3a-d were tested to evaluate their antimicrobial, antiproliferative

  吲唑核中新的 N-甲基和 N-乙基取代是通过 3-(2-氨基苯甲酰氨基) 吲唑和适当的原苯甲酸三甲酯/三乙酯反应来报道的。单晶 X 射线分析证实了 3-(1-乙基-1H-吲唑-3-基)-2苯基喹唑啉-4(3H)-酮衍生物 3f 的 N-乙基化位置。测试了化合物 11a-d 和 3a-d 以评估它们的抗微生物、抗增殖和 COX 抑制活性，显示出稀少或中等的抗增殖活性以及一些对 COX-1 和 COX-2 的抑制活性。
• Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20040254177A1

  公开（公告）日：2004-12-16

  Compounds which are 3-aminoindazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本发明揭示了3-氨基吲唑衍生物或其药学上可接受的盐，以及包含它们的制药组合物。这些化合物或组合物在治疗由蛋白激酶活性改变引起和/或相关的疾病方面具有用途，例如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病。
• AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1432416A1

  公开（公告）日：2004-06-30